CanBas Co., Ltd. (JP:4575)

:4575

4575

CanBas Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4575 full AI Analyst Report?

CanBas Co., Ltd. (4575) Price & Analysis

0 Followers

4575 Stock Chart & Stats

¥787.00

-¥23.00(-2.48%)

At close: Jan 08 4:00 PM EST

¥787.00

-¥23.00(-2.48%)

Day’s Range― - ―

52-Week Range¥548.00 - ¥1,558.00

Previous CloseN/A

Volume347.00K

Average Volume (3M)268.48K

Market Cap

¥11.10B

Enterprise Value¥10.27B

Total Cash (Recent Filing)¥2.83B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-61.17

Shares Outstanding19,713,655

10 Day Avg. Volume208,910

30 Day Avg. Volume268,476

Financial Highlights & Ratios

PEG Ratio1.96

Price to Book (P/B)7.69

Price to Sales (P/S)0.00

P/FCF Ratio-29.34

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Monetization ModelA clear licensing-and-collaboration monetization model is a durable strength: it lets CanBas monetize R&D without requiring full commercialization infrastructure. Partner-funded development and milestone/royalty streams provide scalable, non-linear upside as programs advance, supporting long-term business viability.

Debt-free Balance SheetZero reported debt and materially higher equity reduce leverage risk and improve financial flexibility. This structural strength enhances the company’s ability to raise non-dilutive partnerships or finance R&D on better terms, lengthening runway and lowering bankruptcy risk versus leveraged peers.

Focused R&D ExpertiseSpecialization in oncology and antibody therapeutics represents a durable strategic focus aligned with sustained market demand. Deep domain expertise increases odds of meaningful partnerships, attracts collaborators, and can create defensible program value if clinical proof points are attained over the coming months.

Bears Say

Persistent LossesMulti-year operating and net losses mean shareholder capital is being eroded and returns remain negative (ROE still about -39% in 2025). Ongoing unprofitability reduces internal funding capacity and forces reliance on external financing, constraining long-term independence and investment pace.

Chronic Cash BurnSustained negative operating and free cash flow indicates the company will remain dependent on external capital or partnerships. Even with improvement, recurring cash burn increases dilution or refinancing risk and limits ability to self-fund late-stage development, raising execution risk over the medium term.

Near-zero Revenue BaseWith virtually no recurring product revenue, the company’s value is highly binary and tied to future milestone events or licensing deals. This structural revenue gap elevates uncertainty about sustainable cash generation and makes long-term planning and investment dependent on successful partner outcomes.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥548.00 and its highest was ¥1558.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥11.10B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

CanBas Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 58 days.

How were CanBas Co., Ltd.’s earnings last quarter?

CanBas Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥15.48 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.48.

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,713,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

CanBas Co., Ltd. reported an EPS of -¥15.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.